Sale

Sickle Cell Disease Treatment Market

Global Sickle Cell Disease Treatment Market Size, Forecast: By Treatment Type: Medications, Blood Transfusion, Bone Marrow Transplant, Others; By Diseases Type; By Population Type; By Dosage Form; By Drug Type; By End User; By Treatment Channel; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Sickle Cell Disease Treatment Market Outlook

The global sickle cell disease treatment market size was valued at USD 5.38 billion in 2023, driven by rising accessibility to resources and treatment facilities, growing awareness about sickle cell disease treatment, and increasing demand for blood transfusion treatment. The market is forecasted to grow at a CAGR of 16.9% during the forecast period of 2024-2032 to achieve a value of USD 21.92 billion by 2032.

 

Global Sickle Cell Disease Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Increased Demand for Blood Transfusion Treatment to Bolster the Growth of the Global Sickle Cell Disease Treatment Industry

Based on treatment, the blood transfusion segment is predicted to account for a significant market share in the sickle cell disease treatment industry. This increase can be associated with the increased accessibility of blood transfusion treatment compared to other forms of treatment. In addition, blood transfusion helps to treat anaemia and prevent stroke. Furthermore, it is used to dilute the sickled haemoglobin with normal haemoglobin in order to treat chronic pain, acute chest syndrome, splenic sequestration, and other complications. Thus, this segment is estimated to positively catalyse the market growth in the forecast period.

 

North America to Occupy a Substantial Market Share in the Global Sickle Cell Disease Treatment Industry

North America is expected to occupy a substantial share of the sickle cell disease treatment industry in the forecast period. This growth can be attributed to the presence of a large African-American population in the region, which is more susceptible to sickle cell disease. In addition, the rising accessibility to resources and treatment facilities with increased disposable income and highly advanced healthcare infrastructure are also contributing to the growth. Meanwhile, in the African region, in countries such as Cameroon, the Republic of Congo, Gabon, Ghana, and Nigeria, the prevalence of sickle cell disease is between 20% and 30%. At the same time, it is as high as 45% in some parts of Uganda, as stated by the WHO. Moreover, in this region, the majority of children with the most severe form of the disease die prior to the age of 5, usually from an infection or severe blood loss. Thus, the growing awareness about sickle cell disease treatment and the improving healthcare facilities in Africa are expected to provide lucrative growth opportunities to the market.

 

Sickle Cell Disease Treatment: Market Segmentation

Sickle cell disease refers to a commonly found blood disorder. This disease is inherited by the children whose parents carry either sickle cell disease or sickle cell trait. This disease leads to abnormal haemoglobin generation, which is rigid and shaped like a sickle that can get stuck and block blood flow, which causes interference with oxygen delivery. This leads to pain, infections, stroke, acute chest syndrome, organ damage, and other disabilities. In addition, the drastic complications pertaining to sickle cell disease include premature death in some cases.

 

Global Sickle Cell Disease Treatment Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By treatment, the market is divided into:

  • Blood Transfusion 
  • Pharmacotherapy
  • Bone Marrow Transplant

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Sickle Cell Disease Treatment Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Incidences of Sickle Cell Disease to Augment the Growth of the Global Sickle Cell Disease Treatment Industry

According to the WHO statistics, an estimated 5% of the world’s population carries trait genes for haemoglobin disorders, mainly sickle-cell disease and thalassaemia. In addition, more than 300,000 babies with severe haemoglobin disorders are born each year. The countries worldwide and international organisations are strategising initiatives to control and prevent sickle cell disease risks. Moreover, with the growing geriatric population worldwide, which is more susceptible to chronic disorders, governments are increasingly investing in the healthcare sector to reduce mortality risks. As a result, sickle cell disease treatment is in huge demand for the early detection of the disease. For instance, The Kidney Cancer Association (KCA) and the Sickle Cell Disease Association of America, Inc. (SCDAA) partnered to launch a programme called KNOW & TELL to raise awareness about sickle cell trait and its potential connection with a rare type of kidney cancer known as renal medullary carcinoma (RMC). Such initiatives are expected to augment the market growth in the forecast period.

 

Key Industry Players in the Global Sickle Cell Disease Treatment Market

The report gives a detailed analysis of the following key players in the global sickle cell disease treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Emmaus Life Sciences, Inc.
  • Global Blood Therapeutics, Inc.
  • bluebird bio, Inc.
  • Pfizer Inc.
  • Novartis International AG
  • Others

The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model and SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Treatment Type
  • Diseases Type
  • Population Type
  • Dosage Form
  • Drug Type
  • End User
  • Treatment Channel
  • Distribution Channel
  • Region
Breakup by Treatment Type
  • Medications
  • Blood Transfusion
  • Bone Marrow Transplant
  • Others
Breakup by Diseases Type
  • Hemoglobin Sβ0 Thalassemia
  • Hemoglobin Sβ+ Thalassemia
  • Hemoglobin SC
  • Others
Breakup by Population Type
  • Pediatrics
  • Adults
Breakup by Dosage Form
  • Tablet
  • Capsule
  • Parentals
  • Others
Breakup by Drug Type
  • Over the Counter
  • Prescription
Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Bluebird bio, Inc.
  • Pfizer Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Endo Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Mayne Pharma Group Limited
  • CELGENE CORPORATION
  • Ironwood Pharmaceuticals, Inc.
  • Amgen Inc.
  • Zydus Cadila
  • Silver Lake Research Corporation
  • Ionis Pharmaceuticals, Inc.
  • Vertex Pharmaceuticals Incorporated
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Sickle Cell Disease Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Sickle Cell Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Sickle Cell Epidemiology (2016-2031)
    5.3    Europe Sickle Cell Epidemiology (2016-2031)
    5.4    Asia-Pacific Sickle Cell Epidemiology (2016-2031)
    5.5    Latin America Sickle Cell Epidemiology (2016-2031)
    5.6    Middle East & Africa Sickle Cell Epidemiology (2016-2031)
6    Global Sickle Cell Disease Treatment Market Overview 
    6.1    Global Sickle Cell Disease Treatment Market Historical Value (2017-2023) 
    6.2    Global Sickle Cell Disease Treatment Market Forecast Value (2024-2032)
7    Global Sickle Cell Disease Treatment Market Landscape
    7.1    Global Sickle Cell Disease Treatment: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global Sickle Cell Disease Treatment Product Landscape
        7.2.1    Analysis by Treatment Type
        7.2.2    Analysis by Population Type
        7.2.3    Analysis by End User
8    Sickle Cell Disease Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Sickle Cell Disease Treatment Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Sickle Cell Disease Treatment Market Segmentation
    11.1    Global Sickle Cell Disease Treatment Market by Treatment Type
        11.1.1    Market Overview
        11.1.2    Medications
            11.1.2.1    Antibiotics
            11.1.2.2    Pain-Relieving Medications
            11.1.2.3    Hydroxyurea
            11.1.2.4    Others
        11.1.3    Blood Transfusion
        11.1.4    Bone Marrow Transplant
        11.1.5    Others
    11.2    Global Sickle Cell Disease Treatment Market by Diseases Type
        11.2.1    Market Overview
        11.2.2    Hemoglobin Sβ0 Thalassemia
        11.2.3    Hemoglobin Sβ+ Thalassemia 
        11.2.4    Hemoglobin SC
        11.2.5    Others
    11.3     Global Sickle Cell Disease Treatment Market by Population Type
        11.3.1    Market Overview
        11.3.2    Pediatrics
        11.3.3    Adults
    11.4    Global Sickle Cell Disease Treatment Market by Dosage Form
        11.4.1    Market Overview
        11.4.2    Tablet
        11.4.3    Capsule
        11.4.4    Parentals
        11.4.5    Others
    11.5    Global Sickle Cell Disease Treatment Market by Drug Type
        11.5.1    Market Overview
        11.5.2    Over the Counter
            11.5.2.1    Generics
            11.5.2.2    Branded
        11.5.3    Prescription
    11.6    Global Sickle Cell Disease Treatment Market by End User
        11.6.1    Market Overview
        11.6.2    Hospitals
        11.6.3    Specialty Clinics
        11.6.4    Homecare
        11.6.5    Others
    11.7    Global Sickle Cell Disease Treatment Market by Treatment Channel
        11.7.1    Market Overview
        11.7.2    Public
        11.7.3    Private
    11.8    Global Sickle Cell Disease Treatment Market by Distribution Channel
        11.8.1    Market Overview
        11.8.2    Hospital Pharmacy
        11.8.3    Online Pharmacy
        11.8.4    Retail Pharmacy
    11.9    Global Sickle Cell Disease Treatment Market by Region
        11.9.1    Market Overview
        11.9.2    North America
        11.9.3    Europe 
        11.9.4    Asia Pacific
        11.9.5    Latin America
        11.9.6    Middle East and Africa
12    North America Sickle Cell Disease Treatment Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Sickle Cell Disease Treatment Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Sickle Cell Disease Treatment Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Sickle Cell Disease Treatment Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Sickle Cell Disease Treatment Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Bluebird bio, Inc.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Pfizer Inc.
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Novartis AG
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Bristol-Myers Squibb Company
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Endo Pharmaceuticals Inc.
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Teva Pharmaceutical Industries Ltd.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Sun Pharmaceutical Industries Ltd.
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Mayne Pharma Group Limited
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    CELGENE CORPORATION
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Ironwood Pharmaceuticals, Inc.
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11     Amgen Inc. 
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    Zydus Cadila
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
    23.13    Silver Lake Research Corporation
        23.13.1    Financial Analysis
        23.13.2    Product Portfolio
        23.13.3    Demographic Reach and Achievements
        23.13.4    Mergers and Acquisitions
        23.13.5    Certifications
    23.14    Ionis Pharmaceuticals, Inc.
        23.14.1    Financial Analysis
        23.14.2    Product Portfolio
        23.14.3    Demographic Reach and Achievements
        23.14.4    Mergers and Acquisitions
        23.14.5    Certifications
    23.15    Vertex Pharmaceuticals Incorporated
        23.15.1    Financial Analysis
        23.15.2    Product Portfolio
        23.15.3    Demographic Reach and Achievements
        23.15.4    Mergers and Acquisitions
        23.15.5    Certifications
24    Sickle Cell Disease Treatment Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The sickle cell disease treatment market reached a value of USD 5.38 billion in 2023.

The market is projected to expand at a CAGR of 16.9% from 2024 to 2032, growing to USD 21.92 billion by 2032.

The major drivers of the industry include rising accessibility to resources and treatment facilities, increased disposable income, highly advanced healthcare infrastructure, growing awareness about sickle cell disease treatment, and increasing demand for blood transfusion treatment.

The key market trends guiding the growth of the industry include the increasing investments in the healthcare sector and growing geriatric population worldwide.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The significant segments based on treatment include blood transfusion, pharmacotherapy, and bone marrow transplant.

The major players in the industry are Emmaus Life Sciences, Inc., Global Blood Therapeutics, Inc., bluebird bio, Inc., Pfizer Inc., and Novartis International AG, among others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER